Despite the efficiency of GLP-2 analogs in reducing PN dependence, this life-long treatment induces variable responses among SBS patients (Jeppesen et al., 2018) and remains very expensive. The gene discussed is GCG; the disease is macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.